To date, over 700 people have joined the Angiosarcoma project – Corrie Painter
When I was diagnosed with angiosarcoma, my doctor jotted down a number of therapies that were used to treat other cancers, and told me to pick one if I wanted to look at my children and say that I tried.
There was no data to support any one direction over the other and it was unlikely that there ever would be.
So seeing these results presented yesterday at ASCO was beyond impactful for me.
The clinicians who comprised the sarcoma working group for the Alliance for Clinical Trials invited me to present data from the fledgling Angiosarcoma Project in 2018. The data suggested that there were patients with high TMB having durable responses to checkpoint inhibitors. With that data still projected on the screen, the working group conceived of this study.
In my wildest dreams, I did not think I’d live to see this come to fruition, nor that the results would be this striking.
To date, over 700 people have joined the Angiosarcoma project.
One of the most important lessons of my professional career has been to never underestimate what can be accomplished if the right incentive structures are put in place. To life!
Source: Corrie Painter/Linkedin
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023